Circulating levels of citrullinated and MMP-degraded vimentin (VICM) in liver fibrosis related pathology

E. Vassiliadis, C. P. Oliveira, M. R. Alvares-da-Silva, C. Zhang, F. J. Carrilho, J. T. Stefano, F. Rabelo, L. Pereira, C. R. Kappel, K. Henriksen, S. S. Veidal, B. Vainer, K. L. Duffin, C. Christiansen, D. J. Leeming, M. Karsdal

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


Aim: To investigate whether increased levels of vimentin citrullinated peptides identified by MS in articular cartilage can be measured in pathologies other than rheumatoid arthritis and be utilised for diagnostic purposes. Methods: A monoclonal antibody against the sequence RLRSSVPGV-citrulline (VICM) was developed and evaluated in a carbon tetrachloride (CCl4) (n=52 + 28 controls) rat model of liver fibrosis and two clinical cohorts of adult patients with hepatitis C (HCV) (n=92) and non-alcoholic fatty liver disease (NAFLD) (n=62), and compared to healthy controls. Results: In CCl4-treated rats, mean systemic VICM levels increased 31% at week 12 (176 ng/mL, P
TidsskriftAmerican Journal of Translational Research
Udgave nummer4
Sider (fra-til)403-414
Antal sider12
StatusUdgivet - 2012